[
ZyVersa Therapeutics Announces Published Data Showing Inflammasome ASC Inhibitor IC 100 Decreases Microglial Inflammasome Activation and Alpha-Synuclein That Contribute to Neurodegeneration in Parkins
[og_img]
https://www.investing.com/news/press-releases/zyversa-therapeutics-announces-published-data-showing-inflammasome-asc-inhibitor-ic-100-decreases-microglial-inflammasome-activation-and-alphasynuclein-that-contribute-to-neurodegeneration-in-parkins-93CH-4010604
Investing.com
ZyVersa Therapeutics Announces Published Data Showing Inflammasome ASC Inhibitor IC 100 Decreases Microglial Inflammasome Activation and Alpha-Synuclein That Contribute to Neurodegeneration in Parkins
Related articles